证券代码：688273 证券简称：麦澜德 公告编号：2024-067 南京麦澜德医疗科技股份有限公司 2024 年第四次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2024 年 11 月 13 日 （二） 股东大会召开的地点：南京市雨花台区凤展路 32 号 A2 栋北公司会议室 1、本次会议由公司董事会召集，董事长杨瑞嘉先生主持； 2、会议采用现场投票及网络投票的方式进行表决； 3、本次会议的召集、召开、表决方式符合《公司法》等有关法律、法规及本公 司《公司章程》的有关规定，会议合法有效。 （五） 公司董事、监事和董事会秘书的出席情况 二、 议案审议情况 （一） 非累积投票议案 1、 议案名称：《关于变更公司经营范围、修订<公司章程>并办理工商登记的议 案》 审议结果：通过 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人 ...

南京麦澜德医疗科技股份有限公司 2024 年第四次临时股东大会会议资料 证券代码：688273 证券简称：麦澜德 南京麦澜德医疗科技股份有限公司 2024 年第四次临时股东大会会议资料 2024 年 11 月 南京麦澜德医疗科技股份有限公司 2024 年第四次临时股东大会会议资料 目 录 | 2024 | 年第四次临时股东大会会议须知 | 3 | | --- | --- | --- | | 2024 | 年第四次临时股东大会会议议程 | 5 | | 2024 | 年第四次临时股东大会会议议案 | | 议案一：关于变更公司经营范围、修订《公司章程》并办理工商登记的议案...................7 南京麦澜德医疗科技股份有限公司 2024 年第四次临时股东大会会议资料 南京麦澜德医疗科技股份有限公司 2024 年第四次临时股东大会会议须知 为维护全体股东的合法权益，确保南京麦澜德医疗科技股份有限公司（以下 简称 "公司"）股东大会顺利进行，根据《中华人民共和国证券法》、《中华人民 共和国公司法》等法律法规及《南京麦澜德医疗科技股份有限公司章程》和公司 《股东大会议事规则》的相关规定，制定以下会议须知， ...

Group 1: Financial Performance - The company's Q3 2024 revenue reached 1.02 billion CNY, representing a year-on-year increase of 18.75% [1] - The net profit attributable to shareholders for Q3 2024 was 23.46 million CNY, a decrease of 9.39% year-on-year [1] - The net profit after deducting non-recurring items was 22.35 million CNY, showing a slight increase of 0.46% year-on-year [1] - For the first three quarters of 2024, the revenue was 3.31 billion CNY, with a year-on-year growth of 13.81% [2] - The net profit attributable to shareholders for the first three quarters was 96.07 million CNY, reflecting a year-on-year increase of 13.37% [2] - The net profit after deducting non-recurring items for the first three quarters was 88.41 million CNY, with a year-on-year growth of 22.81% [2] Group 2: Strategic Development - The company is focusing on both consumer healthcare and serious medical fields, aiming for innovation and development in pelvic floor rehabilitation [2][3] - The market for pelvic floor dysfunction (PFD) treatment is expanding, with increasing demand for clinical rehabilitation medical devices [3] - The company has launched a new intelligent diagnosis and treatment system, PI-ONE, to enhance its market position in pelvic floor rehabilitation [3] - The company plans to continue expanding into "more serious" and "more consumer" healthcare sectors to seek new growth points [3][4] Group 3: Investor Relations and Future Outlook - The company is considering stock buybacks and equity incentives to enhance shareholder value [4] - There are concerns regarding the company's ability to break through its profit bottleneck, with a focus on optimizing operations and improving efficiency [4] - The company acknowledges the competitive landscape in the consumer healthcare sector but emphasizes its commitment to innovation and maintaining a competitive edge [3][4] Group 4: Risk Warning - Any forecasts or strategic plans mentioned should not be interpreted as commitments or guarantees regarding the company's future performance [4]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 南京麦澜德医疗科技股份有限公司 关于第二期以集中竞价交易方式回购公司股份的 进展公告 | 回购方案首次披露日 | 2024/7/2，由控股股东杨瑞嘉先生和史志怀先生提议 | | --- | --- | | 回购方案实施期限 | 待第二届董事会第八次会议审议通过后 12 个月 | | 预计回购金额 | 2,000 万元~4,000 万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 万股 103.00 | | 累计已回购股数占总股本比例 | 1.03% | | 累计已回购金额 | 万元 2,002.1020 | | 实际回购价格区间 | 18.57 元/股~19.99 元/股 | 证券代码：688273 证券简称：麦澜德 公告编号：2024-066 一、 回购股份的基本情况 公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported stable revenue growth with a high growth continuation in reproductive anti-aging [1] - In Q3 2024, the company achieved revenue of approximately 102 million yuan, a year-on-year increase of 18.75%, and a net profit attributable to shareholders of 23 million yuan, a year-on-year increase of 9.39% [1] - The reproductive rehabilitation business has shown significant growth, with a revenue increase of 122% year-on-year in the first half of 2024 [1] - The company has established a wholly-owned subsidiary, Nanjing Weizhilian Medical Equipment Co., Ltd., focusing on providing comprehensive solutions for reproductive anti-aging [1][2] - The company continues to increase R&D spending, with R&D expenses in Q3 2024 amounting to 14 million yuan, accounting for 13.89% of revenue [1] Financial Summary - For the first three quarters of 2024, the company achieved revenue of 331 million yuan, a year-on-year increase of 13.81%, and a net profit of 96 million yuan, a year-on-year increase of 13.37% [1] - The projected revenues for 2024-2026 are expected to be 421 million yuan, 519 million yuan, and 639 million yuan, with year-on-year growth rates of 23.4%, 23.4%, and 23.1% respectively [2] - The projected net profits for the same period are expected to be 114 million yuan, 146 million yuan, and 184 million yuan, with corresponding year-on-year growth rates of 26.5%, 28.4%, and 26.1% [2] - The company maintains a gross profit margin of approximately 72.35% and a net profit margin of about 30.41% [1]

Financial Performance - The company's operating revenue for Q3 2024 was ¥102,193,925.70, representing an increase of 18.75% compared to the same period last year[2] - The net profit attributable to shareholders for Q3 2024 was ¥23,463,908.03, showing a decrease of 9.39% year-on-year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥22,354,745.79, with a slight increase of 0.46% compared to the previous year[2] - The basic earnings per share for Q3 2024 was ¥0.2389, down by 7.19% from the same period last year[3] - Operating profit for the third quarter was CNY 113,370,138.56, up from CNY 97,638,838.14 in the previous year, reflecting a growth of 16.5%[17] - Net profit attributable to shareholders of the parent company for the third quarter was CNY 96,070,603.10, compared to CNY 84,737,526.88 in the same quarter of 2023, marking an increase of 13.7%[18] - The total comprehensive income for the third quarter was CNY 100,527,812.13, up from CNY 86,568,338.81 in the previous year, reflecting a growth of 15.9%[18] Research and Development - Research and development expenses totaled ¥15,604,342.74 for Q3 2024, an increase of 11.07% year-on-year, accounting for 15.27% of operating revenue[3] - Research and development expenses for the first three quarters were CNY 40,616,481.48, slightly down from CNY 42,856,112.93 in the same period last year, indicating a decrease of 5.2%[16] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,514,870,439.51, a decrease of 1.24% compared to the end of the previous year[3] - The equity attributable to shareholders at the end of the reporting period was ¥1,309,593,471.36, down by 2.69% from the previous year[3] - The company's total liabilities increased to CNY 167,379,465.15 from CNY 158,603,955.36, representing a rise of 11.2%[15] - The total equity attributable to shareholders decreased to CNY 1,309,593,471.36 from CNY 1,345,778,874.02, a decline of 2.7%[15] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥56,353,866.39, reflecting a decrease of 26.55% year-on-year[2] - The net cash flow from operating activities for the first three quarters of 2024 is CNY 56,353,866.39, a decrease of 26.4% compared to CNY 76,726,299.95 in the same period of 2023[20] - Total cash inflow from operating activities increased to CNY 353,482,030.85, up 9.2% from CNY 323,593,481.32 in the previous year[20] - Cash outflow from operating activities rose to CNY 297,128,164.46, an increase of 20.3% compared to CNY 246,867,181.37 in 2023[20] - The net cash flow from investment activities is -CNY 348,565,156.19, an improvement from -CNY 574,480,313.22 in 2023[20] - The net cash flow from financing activities is -CNY 125,598,319.37, worsening from -CNY 73,833,636.78 in 2023[21] Investments and Other Financials - The company received government subsidies amounting to ¥398,149.08 during the reporting period, contributing to its non-recurring gains[4] - The company received CNY 1,027,549,000.00 from the recovery of investments, a decrease from CNY 3,053,832,000.00 in 2023[20] - The company reported a financial income of CNY 8,129,424.10, down from CNY 11,138,245.91 in the previous year, a decrease of 26.0%[16] Shareholder Actions - The company repurchased 2,140,000 shares, representing 2.14% of its total shares outstanding as of September 30, 2024[10] Other Observations - The company has not disclosed any new product developments or market expansion strategies in the current report[11]

证券代码：688273 证券简称：麦澜德 公告编号：2024-065 南京麦澜德医疗科技股份有限公司 关于召开 2024 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2024 年 11 月 4 日（星期一） 上午 9:00-10:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2024 年 10 月 28 日（星期一）至 11 月 1 日（星期五）16:00 前登录上证路演中心网站首页点击 "提问预征集"栏目或通过公司邮箱 （mld@medlander.com）进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 南京麦澜德医疗科技股份有限公司（以下简称"公司"）于 2024 年 10 月 29 日发布公司 2024 年第三季度报告，为便于广大投资者更全面深入地了解公司 2024 年第三季度经 ...

南京麦澜德医疗科技股份有限公司 章 程 二〇二四年十月 | 第一章 | 总则 4 | | --- | --- | | 第二章 | 经营宗旨和经营范围 5 | | 第三章 | 股份 6 | | 第一节 | 股份发行 6 | | 第二节 | 股份增减和回购 7 | | 第三节 | 股份转让 9 | | 第四章 | 股东和股东大会 9 | | 第一节 | 股东 9 | | 第二节 | 股东大会的一般规定 12 | | 第三节 | 股东大会的召集 17 | | 第四节 | 股东大会的提案与通知 18 | | 第五节 | 股东大会的召开 20 | | 第六节 | 股东大会的表决和决议 23 | | 第五章 | 董事会 28 | | 第一节 | 董事 28 | | 第二节 | 独立董事 31 | | 第三节 | 董事会 37 | | 第四节 | 董事会专门委员会 42 | | 第六章 | 总经理及其他高级管理人员 43 | | 第七章 | 监事会 46 | | 第一节 | 监事 46 | | 第二节 | 监事会 47 | | 第八章 | 财务会计制度、利润分配和审计 49 | | 第一节 | 财务会计制度 49 | | ...

证券代码：688273 证券简称：麦澜德 公告编号：2024-064 南京麦澜德医疗科技股份有限公司 关于召开 2024 年第四次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2024 年第四次临时股东大会 召开日期时间：2024 年 11 月 13 日 15 点 00 分 召开地点：南京市雨花台区凤展路 32 号 A2 栋北 公司会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2024 年 11 月 13 日 至 2024 年 11 月 13 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过互联 股东大会召开日期：2024年11月13日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 （二） 股东大会召集人：董 ...

截至本公告披露日，朱必胜先生未直接持有公司股份，通过南京鸿澜德尚企 业管理合伙企业（有限合伙）、南京蔚澜佳企业管理合伙企业（有限合伙）合计 间接持有公司股份 138,569 股。朱必胜先生辞去公司副总经理职务后，将继续严 格遵守《上海证券交易所科创板股票上市规则》等相关法律法规及在公司首次公 开发行股票时所作的相关承诺。 朱必胜先生的辞职不会对公司日常管理、生产经营产生重大影响。朱必胜先 生在担任公司副总经理期间恪尽职守、勤勉尽责，在公司规范运作方面发挥了积 极作用。在此，公司及公司董事会对朱必胜先生在任职公司副总经理期间为公司 作出的贡献表示衷心感谢。 特此公告。 南京麦澜德医疗科技股份有限公司（以下简称"公司"）董事会于近日收到 公司副总经理朱必胜先生递交的书面辞职报告。因工作调整原因，朱必胜先生申 请辞去公司副总经理职务。辞去公司副总经理职务后，朱必胜先生仍担任公司全 资子公司南京薇之澜医疗器械有限公司总经理和控股子公司南京锐诗得医疗科 技有限公司运营副总经理，继续负责子公司的业务发展和管理工作。根据《公司 法》《公司章程》等相关法律法规的规定，朱必胜先生的辞职报告自送达公司董 事会之日起生效。 证券代 ...